$ 7.98
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza...
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBIT
Target Price
The average target price of NVAX is 13 and suggests 61% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
